Alnylam Pharmaceuticals
ALNY
#546
Rank
โ‚ฌ34.47 B
Marketcap
264,43ย โ‚ฌ
Share price
-2.33%
Change (1 day)
92.95%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of March 2025 : โ‚ฌ1.14 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚ฌ1.14 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚ฌ1.24 B5.47%
2023-12-31โ‚ฌ1.18 B-4.06%
2022-12-31โ‚ฌ1.23 B39.73%
2021-12-31โ‚ฌ0.88 B107.88%
2020-12-31โ‚ฌ0.42 B56.24%
2019-12-31โ‚ฌ0.27 B934.23%
2018-12-31โ‚ฌ26.22 M4.88%
2017-12-31โ‚ฌ25 M-82.47%
2016-12-31โ‚ฌ0.14 B
2007-12-31โ‚ฌ4.62 M-33.15%
2006-12-31โ‚ฌ6.92 M10.91%
2005-12-31โ‚ฌ6.24 M17.6%
2004-12-31โ‚ฌ5.3 M259.52%
2003-12-31โ‚ฌ1.47 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚ฌ0.34 B-70.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ2.37 B 107.80%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.18 B 3.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.43 B-62.13%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.23 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ27.48 B 2,302.35%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ20.02 B 1,650.18%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ14.88 B 1,201.36%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel